High throughput screening assays will be used in expanded projects to test compounds against G protein-coupled receptors, a major area of disease targets
PerkinElmer has been awarded an expanded contract with AstraZeneca R and D Montreal.
PerkinElmer's high throughput screening (HTS) assay technologies will be used in expanded projects that test AstraZeneca's compounds against a defined selection of G protein-coupled receptors (GPCRs), a major area of disease targets currently under study.
This agreement follows a six-year collaboration between the two companies.
The screening contract will be deployed at PerkinElmer's assay and screening service centre in Montreal.
"Because of the success of the screening program and the consistent high level of service we have received from PerkinElmer, we are pleased to expand our relationship into broader high throughput screening activities," said Philippe Walker, vice-president, discovery at AstraZeneca R and D Montreal.
"We are confident that our partners at PerkinElmer will continue to provide integrated, powerful screening solutions as we look to maximize our drug discovery programmes".
AstraZeneca's 'Directed library screening' approach involves the rapid testing of combinatorial libraries against a panel of diverse GPCR targets. Based on the results, new sets of compounds are designed and synthesised by AstraZeneca, which are then tested by PerkinElmer in a panel of GPCRs.
This iterative process enables AstraZeneca to rapidly identify potent and selective compounds for critical targets.
In addition to the Directed library screening programme, the new contract includes an expanded offering of functional HTS assays based on PerkinElmer reagent platforms, such as AlphaScreen, ScreenReady Targets and Membrane Target Systems, as well as sample preparation and detection platforms, such as TopCount, PlateTrak, ImageTrak and Multiprobe.
"AstraZeneca has consistently proven its commitment to developing critical new drugs for therapeutic treatments.
"This commitment has fueled the expansion of our current screening service capabilities for pharmaceutical drug discovery programs," said Peter Coggins, president, PerkinElmer Life and Analytical Sciences.
"We look forward to continuing our relationship with AstraZeneca and helping our partner bring new treatments to market quickly, cost-effectively and responsibly."
